Pulmonary complications of solid organ and hematopoietic stem cell transplantation

被引:219
作者
Kotloff, RM
Ahya, VN
Crawford, SW
机构
[1] Univ Penn, Med Ctr, Sect Adv Lung Dis & Lung Transplantat, Pulm Allergy & Crit Care Div, Philadelphia, PA 19027 USA
[2] Naval Med Ctr, Div Pulm & Crit Care, San Diego, CA USA
关键词
hematopoietic stem cell transplantation; organ transplantation; pneumonia;
D O I
10.1164/rccm.200309-1322SO
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The ability to successfully transplant solid organs and hematopoietic stem cells represents one of the landmark medical achievements of the twentieth century. Solid organ transplantation has emerged as the standard of care for select patients with severe vital organ dysfunction and hematopoietic stem cell transplantation has become an important treatment option for patients with a wide spectrum of nonmalignant and malignant hematologic disorders, genetic disorders, and solid tumors. Although advances in surgical techniques, immunosuppressive management, and prophylaxis and treatment of infectious diseases have made long-term survival an achievable goal, transplant recipients remain at high risk for developing a myriad of serious and often life-threatening complications. Paramount among these are pulmonary complications, which arise as a consequence of the immunosuppressed status of the recipient as well as from such factors as the initial surgical insult of organ transplantation, the chemotherapy and radiation conditioning regimens that precede hematopoietic stem cell transplantation, and alloimmune mechanisms mediating host-versus-graft and graft-versus-host responses. As the population of transplant recipients continues to grow and as their care progressively shifts from the university hospital to the community setting, knowledge of the pulmonary complications of transplantation is increasingly germane to the contemporary practice of pulmonary medicine.
引用
收藏
页码:22 / 48
页数:27
相关论文
共 351 条
[1]   OUTCOME OF RECIPIENTS OF BONE-MARROW TRANSPLANTS WHO REQUIRE INTENSIVE-CARE UNIT SUPPORT [J].
AFESSA, B ;
TEFFERI, A ;
HOAGLAND, HC ;
LETENDRE, L ;
PETERS, SG .
MAYO CLINIC PROCEEDINGS, 1992, 67 (02) :117-122
[2]   Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation [J].
Afessa, B ;
Litzow, MR ;
Tefferi, A .
BONE MARROW TRANSPLANTATION, 2001, 28 (05) :425-434
[3]   Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients [J].
Afessa, B ;
Tefferi, A ;
Litzow, MR ;
Krowka, MJ ;
Wylam, ME ;
Peters, SG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (05) :641-645
[4]   Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients [J].
Afessa, B ;
Tefferi, A ;
Litzow, MR ;
Peters, SG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (10) :1364-1368
[5]   Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain [J].
Aguado, JM ;
Herrero, JA ;
Gavalda, J ;
TorreCisneros, J ;
Blanes, M ;
Rufi, G ;
Moreno, A ;
Gurgui, M ;
Hayek, M ;
Lumbreras, C ;
Morales, JM ;
Pahissa, A ;
Margerit, C ;
Prada, JL ;
Kindelan, JM ;
Ros, F ;
Pallardo, LM ;
Carratala, J ;
Gudiol, F ;
Gonzalez, J ;
Vilardell, J ;
Guirado, L ;
Rabella, N .
TRANSPLANTATION, 1997, 63 (09) :1278-1286
[6]  
AGUSTI C, 1995, AM J RESP CRIT CARE, V151, P1006
[7]   Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis [J].
Akalin, E ;
Sehgal, V ;
Ames, S ;
Hossain, S ;
Daly, L ;
Barbara, M ;
Bromberg, JS .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :731-735
[8]  
ALBELDA SM, 1985, AM REV RESPIR DIS, V131, P115
[9]  
*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_
[10]  
American Thoracic Society, 2001, AM J RESP CRIT CARE, V164, P1319